The angiotensin-(1-7)/ACE2/mas receptor axis emerges as a counterregulatory arm of the renin-angiotensin system and a potential target for therapeutic interventions in hypertension and renal disease.
The study of experimental hypertension and the development of drugs with selective inhibitory effects on the enzymes and receptors constituting the components of the circulating and tissue renin-angiotensin systems have led to newer concepts of how this system participates in both physiology and pathology. Over the last decade, a renewed emphasis on understanding the role of angiotensin-(1-7) and angiotensin-converting enzyme 2 in the regulation of blood pressure and renal function has shed new light on the complexity of the mechanisms by which these components of the renin angiotensin system act in the heart and in the kidneys to exert a negative regulatory influence on angiotensin converting enzyme and angiotensin II. The vasodepressor axis composed of angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor emerges as a site for therapeutic interventions within the renin-angiotensin system. This review summarizes the evolving knowledge of the counterregulatory arm of the renin-angiotensin system in the control of nephron function and renal disease.
Ferrario et al. (Thu,) conducted a review in Hypertension and renal disease. Angiotensin-(1-7)/ACE2/mas receptor axis was evaluated. The angiotensin-(1-7)/ACE2/mas receptor axis emerges as a counterregulatory arm of the renin-angiotensin system and a potential target for therapeutic interventions in hypertension and renal disease.